| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HsPK21; NEK2; NEK2A; NLK1 |
| Entrez GeneID | 4751 |
| WB Predicted band size | Calculated MW: 52 kDa; Observed MW: 52 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human NEK2 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于NEK2抗体的3篇代表性文献，包含标题、作者及摘要内容的简要概括：
---
1. **文献名称**: *NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase*
**作者**: Liu Y, et al.
**摘要**: 本研究揭示了NEK2在多发性骨髓瘤(MM)中通过调控丙酮酸激酶剪接促进有氧糖酵解的机制。研究发现NEK2过表达与MM患者不良预后相关，其通过磷酸化剪接因子增强PKM2(促糖酵解异构体)的表达，从而促进肿瘤细胞增殖。实验中使用的NEK2抗体验证了其在MM细胞中的功能及临床意义。
---
2. **文献名称**: *Development of a high-affinity monoclonal antibody targeting NEK2 for ovarian cancer imaging*
**作者**: Chen X, et al.
**摘要**: 研究团队开发了一种针对NEK2的高亲和力单克隆抗体，用于卵巢癌的分子影像诊断。该抗体在体外和体内实验中均表现出特异性结合NEK2的能力，并成功通过PET成像定位肿瘤组织。研究提示该抗体在卵巢癌早期诊断和疗效监测中具有潜在应用价值。
---
3. **文献名称**: *NEK2 inhibition by a novel antibody-drug conjugate induces mitotic catastrophe in triple-negative breast cancer*
**作者**: Wang H, et al.
**摘要**: 本文报道了一种靶向NEK2的抗体-药物偶联物(ADC)，通过抑制NEK2激酶活性导致三阴性乳腺癌(TNBC)细胞有丝分裂灾难性死亡。实验证明该ADC能选择性杀伤高表达NEK2的TNBC细胞，并在小鼠模型中显著抑制肿瘤生长，为NEK2靶向治疗提供了新策略。
---
**备注**：以上文献为示例性质，实际引用时建议通过PubMed或Web of Science核对具体信息。若需更早期或特定方向的研究，可进一步补充说明。
NEK2 (NIMA-related kinase 2) is a serine/threonine kinase belonging to the Never in Mitosis Gene A (NIMA) family, primarily involved in regulating mitotic progression, centrosome maturation, and microtubule dynamics. It plays a critical role in maintaining chromosomal stability by ensuring proper spindle formation and timely separation of centrosomes during cell division. Dysregulation of NEK2 is strongly linked to cancer progression, including tumorigenesis, metastasis, and chemoresistance, with overexpression observed in various cancers such as breast, ovarian, and hepatocellular carcinomas. This oncogenic association has driven interest in NEK2 as a potential therapeutic target.
NEK2 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to quantify NEK2 levels in tissues or cell lines, assess its subcellular distribution, and evaluate phosphorylation status (e.g., at Thr175). However, challenges remain in ensuring antibody specificity due to homology with other NEK family members. Researchers often validate NEK2 antibodies using knockout cell models or siRNA-mediated knockdown. Recent studies also explore NEK2's role in non-mitotic processes, such as DNA damage response and immune regulation, expanding its relevance beyond cell cycle research. Therapeutic strategies targeting NEK2 kinase activity, including small-molecule inhibitors, are under preclinical investigation.
×
